| Income statement (USD) | FY 2025 ended Mar 31, 2025 | FY 2024 ended Mar 31, 2024 | FY 2023 ended Mar 31, 2023 | FY 2022 ended Mar 31, 2022 | FY 2022 ended Mar 31, 2021 |
|---|---|---|---|---|---|
| Gross profit | -53.1K | 50.6K | -1.4K | -9.4K | |
| Research and development | 1.78M | 1.56M | 2.18M | 433.7K | 120.2K |
| Net income | -6.07M | -6.74M | -5.46M | -1.75M | -672.9K |
From Virax Biolabs Group Ltd's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.